ADGI ADAGIO THERAPEUTICS INC

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference

Fireside Chat Date: Tuesday, November 7, 2023

Fireside Chat Time: 3:50 PM ET

Location: New York, NY

Evercore ISI 6th Annual HealthCONx Conference

Fireside Chat Date: Thursday, November 30, 2023

Fireside Chat Time: 10:50 AM ET

Location: Miami, FL

Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit  to learn more.



Contacts:

Scott Young

(781) 208-1747

Gabriella Linville-Engler

(781) 208-0160



EN
31/10/2023

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comp...

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use...

May 23, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medi...

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requestsIn contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Ameri...

May 21, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Reports First Quarter 2025 Financial Results and Recent Busine...

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of...

May 15, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antib...

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development of vaccines and monoclonal antibodies (mAbs) for COVID-19 prevention, in order to rebuild American’s trust in scientific data, public health recommendations, and preventatives,...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect In...

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their H.C. Wainwright r...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch